AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma
The AADN score can distinguish the prognostic risk of uHCC patients treated with TACE, sintilimab and lenvatinib, provides a basis for individualized treatment decision-making, and have clinical application prospect.
Authors
- Liying Ren
- Yuan-ping Zhou
- Shaoping She (ORCID: https://orcid.org/0000-0001-9796-9253)
- Hongsong Chen
- Xu Cong
- Ran Fei
- Shao-Wei Mu
- Xue Zhang
- Wan-Ying Qin
- Min-Jun Liao
- Dong-Bo Chen
Institutions
- Peking University (CN)
- Nanfang Hospital (CN)
- Peking University People's Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- World Journal of Gastroenterology
- Published
- 2025-12-26
- DOI
- https://doi.org/10.3748/wjg.v31.i48.113856
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32